Syndicated News Headlines - Promo

ProPhase Dips on Moving Karkus up Ladder

ProPhase Labs, Inc. (NASDAQ: PRPH) fell Tuesday, as the company, a next generation biotech, genomics, therapeutics and diagnostics company, today reported that Jason Karkus, one of the driving forces behind ProPhase Diagnostics, becomes President of Nebula Genomics, a wholly-owned subsidiary of ProPhase Labs.

Jason Karkus’s remarkable journey at ProPhase Diagnostics is marked by his exemplary leadership and business acumen that led to the successful inception and expansion of the Company’s Covid laboratory testing venture, generating an impressive $200 million in revenue during 2021 and 2022. This fiscal achievement fueled ProPhase’s growth and strategic acquisition of Nebula Genomics.

In his new role, Karkus aims to amplify the Nebula Genomics business-to-business operations, as well as its exciting direct-to-consumer Whole Genome Sequencing (WGS) model. This strategic move is in line with ProPhase’s evolution from a high complexity molecular Covid testing laboratory to an advanced WGS pioneer.

The Company’s state-of-the-art WGS lab, featuring four cutting-edge sequencing platforms, including two high-capacity, low cost, WGS machines, sets a precedent in the United States that the Company believes well positions its WGS lab to revolutionize the genomics industry. As ProPhase focuses on its WGS business lines, Karkus’ leadership, energy and vision are expected to be a driving force.

PRPH shares lost five cents, or 1.1%, to $4.73.

Source link

About The Author

Scroll to Top